{"id":1038258,"date":"2012-04-07T10:10:34","date_gmt":"2012-04-07T10:10:34","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/american-oriental-bioengineering-inc-receives-nyse-notice-of-delisting-or-failure-to-satisfy-a-continued-listing-rule.php"},"modified":"2024-08-17T16:15:24","modified_gmt":"2024-08-17T20:15:24","slug":"american-oriental-bioengineering-inc-receives-nyse-notice-of-delisting-or-failure-to-satisfy-a-continued-listing-rule","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/bioengineering\/american-oriental-bioengineering-inc-receives-nyse-notice-of-delisting-or-failure-to-satisfy-a-continued-listing-rule.php","title":{"rendered":"American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule &#8230;"},"content":{"rendered":"<p><p>    NEWARK, N.J., April 6, 2012 \/PRNewswire-Asia-FirstCall\/ --    American Oriental    Bioengineering, Inc. (NYSE:     AOB -     News) (the \"Company\") today announced that the New York Stock    Exchange (the \"NYSE\") has notified the Company that it is    not in compliance with NYSE rules due to the Company's failure    to timely file its Annual Report on Form 10-K with the    Securities and Exchange Commission.  <\/p>\n<p>    Under NYSE rules, when a Company does not comply with annual    report filing requirements, the NYSE allows a company an    additional six months to file its annual report in order to    regain compliance. In the case of the Company, the annual    report would be due on or before October 29, 2012. If the    Company fails to file its annual report within that time    period, the NYSE may, in its sole discretion, allow the    Company's securities to remain listed for up to an additional    six months or may, in its sole discretion, commence suspension    and delisting procedures.  <\/p>\n<p>    As previously announced, during the performance of the annual    audit of the Company's financial statements for the fiscal year    2011, the Company's auditors, Ernst & Young Hua Ming's    (E&Y), noted certain inconsistencies. As a result,    the Audit Committee has commenced an independent investigation    into the matters identified by E&Y. Although the    Company cannot know at this time how long the investigation    will take, the Company will endeavor to file the Form 10-K as    soon as possible upon the completion of the investigation.  <\/p>\n<p>    About American    Oriental Bioengineering, Inc.  <\/p>\n<p>    American Oriental Bioengineering, Inc. is a pharmaceutical    company dedicated to improving health through the development,    manufacture and commercialization of a broad range of    prescription and over the counter products.  <\/p>\n<p>    Safe Harbor Statement  <\/p>\n<p>    Statements made in this press release are forward-looking and    are made pursuant to the safe harbor provisions of the    Securities Litigation Reform Act of 1995. Such statements    involve risks and uncertainties that may cause actual results    to differ materially from those set forth in these    statements. The economic, competitive, governmental,    technological and other factors identified in the Company's    filings with the Securities and Exchange Commission may cause    actual results or events to differ materially from those    described in the forward looking statements in this press    release. The Company undertakes no obligation to publicly    update or revise any forward-looking statements, whether    because of new information, future events, or otherwise.  <\/p>\n<p>            Contact:          <\/p>\n<p>            American Oriental            Bioengineering, Inc.          <\/p>\n<p>            Hong Zhu          <\/p>\n<\/p>\n<p>Here is the original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/american-oriental-bioengineering-inc-receives-120000271.html\" title=\"American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule ...\" rel=\"noopener\">American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> NEWARK, N.J., April 6, 2012 \/PRNewswire-Asia-FirstCall\/ -- American Oriental Bioengineering, Inc. (NYSE: AOB - News) (the \"Company\") today announced that the New York Stock Exchange (the \"NYSE\") has notified the Company that it is not in compliance with NYSE rules due to the Company's failure to timely file its Annual Report on Form 10-K with the Securities and Exchange Commission <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/bioengineering\/american-oriental-bioengineering-inc-receives-nyse-notice-of-delisting-or-failure-to-satisfy-a-continued-listing-rule.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246861],"tags":[],"class_list":["post-1038258","post","type-post","status-publish","format-standard","hentry","category-bioengineering"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1038258"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1038258"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1038258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1038258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1038258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1038258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}